1 month ago
ChrysCapital Acquires Majority Stake in Novartis India, Rebrands Company
A private‑equity company called ChrysCapital bought most of a drug company in India that used to belong to a Swiss company.
They paid about 1,446 crore rupees for it.
Now the Indian company will have a new name and run on its own.
A new boss, Dr Vikas Gupta, will lead it.
ChrysCapital wants to grow the company by making more generic medicines for people in India.
Private equity firm ChrysCapital has acquired a 70.68% controlling stake in Novartis India Limited (NIL) from its parent company Novartis AG.
The deal, valued at ₹1,446 crore, marks ChrysCapital’s first majority investment in India’s pharmaceutical sector.
NIL will rebrand and operate independently, focusing on building a leading branded‑generics platform across multiple therapeutic areas.
New leadership includes Dr Vikas Gupta as CEO/MD and independent directors Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha.
The transaction was advised by Kotak, Freshfields, AZB & Partners, Ernst & Young, Shardul Amarchand Mangaldas & Co, Alvarez & Marsal, Dhruva Advisors, and Price Waterhouse & Co.
- Who
- Private equity firm ChrysCapital and Swiss drugmaker Novartis AG
- What
- Acquisition of a 70.68% controlling stake in Novartis India Limited
- Where
- India
- When
- July 30, 2026
- Why
- To build a leading branded‑generics platform and separate NIL from its parent
Key facts
- Stake acquired
- 70.68%
- Deal value
- ₹1,446 crore
- New CEO
- Dr Vikas Gupta
- New name
- TBD
- Date
- July 30, 2026
Quotes
Dr Vikas Gupta
Chief Executive and Managing Director, Novartis India Limited
“We carry forward decades of scientific rigour and physician trust – from that strong foundation and with ChrysCapital’s backing we have the resources and focus to grow our portfolio with purpose, reach more patients, and build on what this organization has always stood for.”
thehindubusinessline.com
“Combined with NIL’s legacy brands and market standing, ChrysCapital believes the foundation for long‑term value creation is firmly in place.”
thehindubusinessline.com
Sources
Related news
Nestlé Sells Supplements Business as India Growth Accelerates
Natco Pharma Expands Beyond Generics Amid Intensifying Competition
Murthy Family Office, Funds Buy Foseco India Stake
Why Kacholia, Singhania ignored falling promoter stakes in healthcare
Indian stocks surge on realty deals, pharma approvals, rail contracts
Piper Serica reshapes portfolio, adds pharma and electronics stocks
Venii Launches Premium All-Leather Open Footwear Brand in India
India's Most Promising Industry Leaders of 2026 Recognized
Kerala High Court scrutinizes Centre's breast cancer drug stance
